Breaking Down Kidney Disease: From Guidelines to Prognostic Profiling

The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.

Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.

FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.

Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.

New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.

Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.

The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.

Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.